Saima Aslam, MD, MS, University of California San Diego Medical Center, San Diego, CA, USA
Rebecca Cogswell, University of Minnesota, Minneapolis, MN, USA
Jennifer Cook, MD, Arizona Sarver Heart Center, Tucson, AZ, USA
Jens Garbade, MD, University of Leipzig, Leipzig, Germany
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA
Christopher Hayward, MD, St. Vincent’s Hospital, Sydney, Australia
Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA
Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX, USA
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna, Italy
Kavitha Muthiah, MBChB, PhD, St. Vincent’s Hospital, Sydney, Australia
Evgenij Potapov, MD, PhD, German Heart Institute, Berlin, Germany
Diyar S. Saeed, MD, PhD, Leipzig Heart Center, Leipzig, Germany
Christopher T. Salerno, MD, St. Vincent's Heart Center, Indianapolis, IN, USA
Palak Shah, MD, MS, Inova Heart & Vascular Institute, Falls Church, VA, USA
Andre Simon, PhD, MD, Harefield Hospital, London, UK

This course is designed to provide essential clinical knowledge and professional skills to facilitate patient identification, selection, pre and post management of surgical and medical aspects involved in durable mechanical circulatory support.

This course is designed at the level of clinicians and allied health professionals who are in the early stages of their careers. This course would also benefit to those who are part of a new program or desire a comprehensive foundational review. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical circulatory support.

At the conclusion of this course, participants will have improved competence and professional performance in their ability to:
 

1. Assess suitability for durable mechanical circulatory support (MCS) implantation.
2. Assess the impact the medical and social factors which influence patient outcomes during short andlong-term MCS.
3. Recognize options for MCS support and the technological differences that may impact pump selectionand patient/device management.
4. Identify appropriate implantation techniques.
5. Identify issues that impact immediate post implant management in the intensive care unit.
6. Manage MCS patients during long-term support.
7. Diagnose and manage common clinical scenarios, adverse events and extreme situations encounteredafter MCS.

Physicians
Accreditation Statement – The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement – ISHLT designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 6.755 contact hours for nurses and 2.5 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.